ERR2598229
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_forebrain
- 8
- umap1_2d
- -4.21968705
- umap2_2d
- 2.802442617
- umap1_3d
- -2.45511933
- umap2_3d
- 2.821768142
- umap3_3d
- -1.50524752
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- MYC_TARGETS_V1+0.560
- G2M_CHECKPOINT+0.540
- MITOTIC_SPINDLE+0.450
- DNA_REPAIR+0.380
- HEDGEHOG_SIGNALING+0.360
- WNT_BETA_CATENIN_SIGNALING+0.360
- PROTEIN_SECRETION+0.300
- MTORC1_SIGNALING+0.290
- NOTCH_SIGNALING+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- IL6_JAK_STAT3_SIGNALING-0.530
- INFLAMMATORY_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- COAGULATION-0.450
- COMPLEMENT-0.440
- ANGIOGENESIS-0.410
- IL2_STAT5_SIGNALING-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598238 | fetal | fetal | 0.971 |
| 2 | ERR2598195 | fetal | fetal | 0.947 |
| 3 | ERR2598206 | fetal | fetal | 0.945 |
| 4 | ERR2598196 | fetal | fetal | 0.940 |
| 5 | ERR2598198 | fetal | fetal | 0.934 |
| 6 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.932 |
| 7 | TCGA-22-5477-01A-01R-1635-07 | — | cohortSQ2 | 0.922 |
| 8 | ERR2598212 | fetal | fetal | 0.916 |
| 9 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.916 |
| 10 | ERR2598235 | fetal | fetal | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.090 | Cobimetinib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |